Department of Neurology, University Hospital Ramón y Cajal, Madrid, Spain.
Department of Neurology, Hospital La Luz, Madrid, Spain.
Eur J Neurol. 2020 Sep;27(9):1738-1741. doi: 10.1111/ene.14273. Epub 2020 May 16.
Specific respiratory tract infections, including COVID-19, may cause smell and/or taste disorders (STDs) with increased frequency. The aim was to determine whether new-onset STDs are more frequent amongst COVID-19 patients than influenza patients.
This was a case-control study including hospitalized patients of two tertiary care centres. Consecutive patients positive for COVID-19 polymerase chain reaction (cases) and patients positive for influenza polymerase chain reaction (historical control sample) were assessed during specific periods, employing a self-reported STD questionnaire.
Seventy-nine cases and 40 controls were included. No significant differences were found in basal features between the two groups. New-onset STDs were significantly more frequent amongst cases (31, 39.2%) than in the control group (5, 12.5 %) [adjusted odds ratio 21.4 (2.77-165.4, P = 0.003)]. COVID-19 patients with new-onset STDs were significantly younger than COVID-19 patients without STDs (52.6 ± 17.2 vs. 67.4 ± 15.1, P < 0.001). Amongst COVID-19 patients who presented STDs, 22 (70.9%) recalled an acute onset and it was an initial manifestation in 11 (35.5%). Twenty-five (80.6%) presented smell disorders (mostly anosmia, 14, 45.2%) and 28 (90.3%) taste disorders (mostly ageusia, 14, 45.2%). Only four (12.9 %) reported concomitant nasal obstruction. The mean duration of STD was 7.5 ± 3.2 days and 12 patients (40%) manifested complete recovery after 7.4 ± 2.3 days of onset.
New-onset STDs were significantly more frequent amongst COVID-19 patients than influenza patients; they usually had an acute onset and were commonly an initial manifestation. The use of STD assessment in anamnesis as a hint for COVID-19 and to support individuals' self-isolation in the current epidemic context is suggested.
特定的呼吸道感染,包括 COVID-19,可能会导致嗅觉和/或味觉障碍(STD)的发生率增加。本研究旨在确定新发 STD 在 COVID-19 患者中是否比流感患者更为常见。
这是一项病例对照研究,纳入了两家三级保健中心的住院患者。在特定时期,对 COVID-19 聚合酶链反应阳性(病例)和流感聚合酶链反应阳性(历史对照样本)的连续患者进行评估,采用自我报告的 STD 问卷。
纳入了 79 例病例和 40 例对照。两组间的基础特征无显著差异。病例组新发 STD 的发生率明显高于对照组(31 例,39.2%比 5 例,12.5%)[校正比值比 21.4(2.77-165.4,P=0.003)]。新发 STD 的 COVID-19 患者明显比无 STD 的 COVID-19 患者年轻(52.6±17.2 岁比 67.4±15.1 岁,P<0.001)。在出现 STD 的 COVID-19 患者中,22 例(70.9%)回忆起急性发作,11 例(35.5%)为首发症状。25 例(80.6%)出现嗅觉障碍(主要为嗅觉丧失,14 例,45.2%),28 例(90.3%)出现味觉障碍(主要为味觉丧失,14 例,45.2%)。仅 4 例(12.9%)报告同时存在鼻塞。STD 的平均持续时间为 7.5±3.2 天,12 例(40%)在发病后 7.4±2.3 天完全恢复。
新发 STD 在 COVID-19 患者中比流感患者更为常见;它们通常具有急性发作的特点,并且常常是首发症状。建议在当前的疫情背景下,将病史中的 STD 评估作为 COVID-19 的提示,并支持个人自我隔离。